EVOFEM BIOSCIENCES INC (EVFM) Stock News
NASDAQ:EVFM - Nasdaq - US30048L2034 - Common Stock - Currency: USD
EVFM Latest News, Press Relases and Analysis
Evofem Biosciences to Present at Emerging Growth Conference
/PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that members of its management team will present at the upcoming Emerging Growth...
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
/PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S...
Evofem Reports Fourth Consecutive Year of Net Sales Growth
/PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended...
Mentions: ADTX
Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO
/PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company a...
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evofem Biosciences (NASDAQ:EVFM) just reported results for the second quarter o...
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q2 2024
Evofem Biosciences just reported results for the second quarter of 2024.
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
/PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third...
Mentions: ADTX
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q1 2024
Evofem Biosciences just reported results for the first quarter of 2024.
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q4 2023
Evofem Biosciences just reported results for the fourth quarter of 2023.
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
Mentions: ADTX
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
Mentions: ADTX
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and its majority-owned subsidiary, Pearsanta Inc., have signed a market development collaboration agreement with Evofem Biosciences (OTCQB: EVFM), a women’s health company. According to the announcement, the agreement involves Pearsanta’s blood-based diagnostic test for endometriosis, which affects an estimated 190 million women globally. The […]
Mentions: ADTX
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
Mentions: ADTX
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
Mentions: ADTX
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
/PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc....
Mentions: ADTX
BioMedNewsBreaks — Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company Update
Evofem Biosciences (OTCQB: EVFM) is reporting on its financial results and corporate update for Q2 2024; the report also included a report on the first half of 2024. Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a merger agreement with Evofem last year; the agreement was amended and […]
Mentions: ADTX
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
/PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the second...
Mentions: ADTX
OTCQB Venture Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
OTCQB Venture Virtual Investor Conference Agenda Announced for August 1st
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ET
Mentions: ADTX
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
/PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a...
Mentions: ADTX
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
Mentions: ADTX
Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC
/PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced today that it has...
Mentions: ADTX
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
/PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) today announced a new market partnership with Hello Alpha, a telemedicine...
Mentions: ADTX
Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter
/PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No....
Mentions: ADTX
Evofem Biosciences Announces Financial Results for the First Quarter of 2024
/PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc....
Mentions: ADTX
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
/PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a...
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
/PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc....
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
/PRNewswire/ -- Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy,...
Mentions: ADTX
